A Single-center, Open-label Study Evaluating the Pharmacokinetics, and Safety of Multiple Dose Oral Brexpiprazole Tablets (1 mg) in Chinese Healthy Subjects
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 May 2019
Price : $35 *
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Agitation; Bipolar disorders; Borderline personality disorders; Major depressive disorder; Post-traumatic stress disorders; Schizophrenia; Sleep disorders
- Focus Pharmacokinetics
- Sponsors Otsuka Beijing Research Institute
- 17 May 2019 Status changed from not yet recruiting to active, no longer recruiting.
- 20 Feb 2019 Planned End Date changed from 30 Jun 2019 to 1 Dec 2019.
- 20 Feb 2019 Planned primary completion date changed from 30 Jan 2019 to 1 Jul 2019.